Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Nash

Showing results (171-180 of 198) with videos related to

Pageof 20
Sort By:
Arthritis and Rheumatism|August 1, 2009
Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritisPaul Emery, Roy M Fleischmann, Larry W Moreland, et al.
The Journal of Rheumatology|December 4, 2009
Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS groupOtylia Kowal-Bielecka, Jerome Avouac, David Pittrow, et al.
Rheumatology and Therapy|June 8, 2020
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension StudyPeter Nash, Laura C Coates, Alan J Kivitz, et al.
The Lancet. Rheumatology|January 26, 2024
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL BalancePeter Nash, Philip J Mease, Dona Fleishaker, et al.
The Journal of Rheumatology|April 17, 2018
Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb TrialMark C Genovese, César Pacheco-Tena, Arturo Covarrubias, et al.
Modern Rheumatology|December 15, 2021
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1)Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, et al.
Arthritis and Rheumatism|January 26, 2013
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic studyDésirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, et al.
Modern Rheumatology|August 3, 2022
Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week resultsYoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, et al.
Annals of the Rheumatic Diseases|May 21, 2015
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search updateMichaela A Stoffer, Monika M Schoels, Josef S Smolen, et al.
International Journal of Rheumatic Diseases|February 28, 2019
2018 update of the APLAR recommendations for treatment of rheumatoid arthritisChak Sing Lau, Faith Chia, Leonila Dans, et al.
Pageof 20

Showing results (171-180 of 198) with videos related to

Sort By:
Pageof 20
Arthritis and Rheumatism|August 1, 2009
Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritisPaul Emery, Roy M Fleischmann, Larry W Moreland, et al.
The Journal of Rheumatology|December 4, 2009
Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS groupOtylia Kowal-Bielecka, Jerome Avouac, David Pittrow, et al.
Rheumatology and Therapy|June 8, 2020
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension StudyPeter Nash, Laura C Coates, Alan J Kivitz, et al.
The Lancet. Rheumatology|January 26, 2024
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL BalancePeter Nash, Philip J Mease, Dona Fleishaker, et al.
The Journal of Rheumatology|April 17, 2018
Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb TrialMark C Genovese, César Pacheco-Tena, Arturo Covarrubias, et al.
Modern Rheumatology|December 15, 2021
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1)Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, et al.
Arthritis and Rheumatism|January 26, 2013
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic studyDésirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, et al.
Modern Rheumatology|August 3, 2022
Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week resultsYoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, et al.
Annals of the Rheumatic Diseases|May 21, 2015
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search updateMichaela A Stoffer, Monika M Schoels, Josef S Smolen, et al.
International Journal of Rheumatic Diseases|February 28, 2019
2018 update of the APLAR recommendations for treatment of rheumatoid arthritisChak Sing Lau, Faith Chia, Leonila Dans, et al.
Pageof 20